Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -41.33%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.34%.
RETURN ON ASSETS (ROA)
-41.33%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.73%
median of 690 covered companies
CURRENT VS SECTOR MEDIAN
-34.52%
vs the sector median at left
Eikon Therapeutics, Inc. Common Stock
Market Cap
$418.06M
Return on Assets (ROA)
-41.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$415.76M
Return on Assets (ROA)
-45.47%
TTM Avg
-26.84%
3Y Avg
-30.13%
5Y Avg
-31.02%
Market Cap
$414.54M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$425.12M
Return on Assets (ROA)
-14.54%
TTM Avg
-48.52%
3Y Avg
-33.40%
5Y Avg
-26.00%
Market Cap
$409.89M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$433.71M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$404.78M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
-68.11%
5Y Avg
-68.11%
Market Cap
$401.26M
Return on Assets (ROA)
-17.62%
TTM Avg
-32.09%
3Y Avg
-24.12%
5Y Avg
-19.05%
Market Cap
$439.67M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $418.06M | -41.33% | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $415.76M | -45.47% | -26.84% | -30.13% | -31.02% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $414.54M | -71.16% | -43.23% | -31.68% | -18.72% |
| Prothena Corporation plc (PRTA)vs › | $425.12M | -14.54% | -48.52% | -33.40% | -26.00% |
| Shoulder Innovations, Inc. (SI)vs › | $409.89M | -23.05% | -30.00% | -27.77% | -27.77% |
| NeoGenomics, Inc. (NEO)vs › | $433.71M | -3.84% | -6.38% | -6.57% | -4.38% |
| Carlsmed, Inc. (CARL)vs › | $404.78M | -30.75% | -34.79% | -68.11% | -68.11% |
| Myriad Genetics, Inc. (MYGN)vs › | $401.26M | -17.62% | -32.09% | -24.12% | -19.05% |
| Editas Medicine, Inc. (EDIT)vs › | $439.67M | -31.15% | -77.61% | -57.20% | -46.24% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $395.51M | -62.39% | -45.13% | -56.85% | -56.85% |
ROA
-41.3%
ROE
-69.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -54.52% |
